[go: up one dir, main page]

WO2022124079A1 - Composition d'émulsion de type huile dans l'eau contenant un catalyseur au platine et son procédé d'utilisation - Google Patents

Composition d'émulsion de type huile dans l'eau contenant un catalyseur au platine et son procédé d'utilisation Download PDF

Info

Publication number
WO2022124079A1
WO2022124079A1 PCT/JP2021/043041 JP2021043041W WO2022124079A1 WO 2022124079 A1 WO2022124079 A1 WO 2022124079A1 JP 2021043041 W JP2021043041 W JP 2021043041W WO 2022124079 A1 WO2022124079 A1 WO 2022124079A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
less
mass
terminated
organopolysiloxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/043041
Other languages
English (en)
Japanese (ja)
Inventor
俊 久保田
知子 佐藤
英夫 秦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP2022568170A priority Critical patent/JPWO2022124079A1/ja
Priority to CN202180074880.5A priority patent/CN116437972A/zh
Publication of WO2022124079A1 publication Critical patent/WO2022124079A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/04—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin

Definitions

  • the present disclosure relates to an oil-in-water emulsified composition containing a platinum catalyst and a method for using the same.
  • platinum catalysts have been used in various applications such as polymer polymerization.
  • Patent Document 1 describes a formulation for application to the skin, a) (i) a highly viscous vinyl-terminated organopoly having a viscosity of 100,000-500,000 cst or cP at 25 ° C. Reactions comprising at least one siloxane, at least one low-viscosity vinyl-terminated organopolysiloxane having a viscosity of 500-50,000 cst or cP at 25 ° C., and at least one hydride-functionalized polysiloxane.
  • It contains a sex element; and (ii) a reactive reinforcing component containing a reinforcing element; and b) a cross-linking component containing a platinum catalyst; the cross-linking component promotes cross-linking of the reactive reinforcing component in situ, resulting in a film.
  • formulations that form on the skin.
  • the platinum catalyst is typically an unstable catalyst with poor storage stability, it is generally stored in a cool and dark place in a state of being dispersed in oil and purged with nitrogen.
  • the platinum catalyst In order to increase the variation of the usage pattern of the platinum catalyst, for example, it is conceivable to use an aqueous phase in combination with the platinum catalyst and the oil phase.
  • the platinum catalyst is sensitive to water, and it has been difficult to stabilize the platinum catalyst in a system containing water. Furthermore, in a system containing water, it was even more difficult to improve the storage stability in a high temperature environment.
  • the subject of the present disclosure is to provide an oil-in-water emulsified composition containing a platinum catalyst, which is excellent in storage stability of the platinum catalyst at high temperatures.
  • An oil-in-water emulsified composition comprising a dispersion medium containing water and oil droplets dispersed in the dispersion medium.
  • the oil droplets contain an oil, an emulsifier, and a catalyst.
  • the oil contains the first unsaturated organopolysiloxane and contains
  • the catalyst contains a platinum complex coordinated with 1,3-divinyltetramethyldisiloxane, and The mass ratio of the first unsaturated organopolysiloxane to the total amount of platinum in the platinum complex is 200 or more.
  • Oil-in-water emulsified composition ⁇ Aspect 2> The composition according to aspect 1, wherein the emulsifier contains a polymer emulsifier.
  • the polymer emulsifiers are (Acrylate / alkyl acrylate (C10-30)) cross-polymer, (acryloyldimethyltaurinammonium ammonium methacrylate / behenes-25 methacrylate) cross-polymer, (hydroxyethyl acrylate / acryloyldimethyltaurine Na) copolymer, PEG.
  • the composition according to aspect 2 which is at least one selected from modified crosspolymer / copolymer siloxane, polyether modified crosspolymer / copolymer siloxane, and polyoxyethylene.
  • the first unsaturated organopolysiloxane is at least one selected from an organopolysiloxane having a vinyl group, a vinyl-terminated organopolysiloxane, and an organopolysiloxane having a vinylized branched chain.
  • the first agent comprises a second unsaturated organopolysiloxane and a hydride-functionalized polysiloxane.
  • the second agent is the oil-in-water emulsified composition according to any one of aspects 1 to 8.
  • ⁇ Aspect 10> Aspect in which the second unsaturated organopolysiloxane is at least one selected from an organopolysiloxane having a vinyl group, a vinyl-terminated organopolysiloxane, and an organopolysiloxane having a vinylized branched chain. 9. The artificial skin forming agent according to 9.
  • the second unsaturated organopolysiloxane is vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoro.
  • the artificial skin-forming agent according to aspect 10 which is at least one selected from a polymer, a vinyl T-structure polymer, a monovinyl-terminated polydimethylsiloxane, a vinylmethylsiloxane tarpolymer, and a vinylmethoxysilane homopolymer.
  • the hydride-functionalized polysiloxanes are hydride-terminated polydimethylsiloxane, hydride-terminated polyphenyl- (dimethylhydrosiloxy) siloxane, hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymer, trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer, and polymethyl.
  • Skin forming agent ⁇ Aspect 14> One of embodiments 9-13, wherein the first agent, the second agent, or both of them comprises at least one selected from fibers, pigments, dyes, thickeners, protective colloid agents, and fillers. The artificial skin-forming agent described.
  • the first agent and the second agent according to any one of embodiments 9 to 14 are encapsulated in separate containers, or separately encapsulated in each compartment of a container having two or more compartments. ,kit.
  • ⁇ Aspect 16> A method of using the artificial skin forming agent according to any one of aspects 9 to 14. After the first agent is applied to the body surface to form the first agent layer, the second agent is applied onto the first agent layer and crosslinked to form an artificial skin. After the second agent is applied to the body surface to form the second agent layer, the first agent is applied onto the second agent layer and crosslinked to form an artificial skin, or After preparing a mixture by mixing the first agent and the second agent, the mixture is applied to the body surface and crosslinked to form an artificial skin. how to use.
  • an oil-in-water emulsified composition containing a platinum catalyst which is excellent in storage stability of the platinum catalyst at high temperatures.
  • the oil-in-water emulsifying composition of the present disclosure is an oil-in-water emulsifying composition containing a dispersion medium containing water and oil droplets dispersed in the dispersion medium, wherein the oil droplets are an oil component, an emulsifier, and the like.
  • a catalyst the oil content contains the first unsaturated organopolysiloxane, the catalyst contains a platinum complex coordinated with 1,3-divinyltetramethyldisiloxane, and the first relative to the total amount of platinum in the platinum complex.
  • the mass ratio of the unsaturated organopolysiloxane of 1 is 200 or more.
  • the oil-in-water emulsified composition of the present disclosure has excellent storage stability of the platinum catalyst at high temperatures, and blackening, reduction of catalytic activity, etc. due to aggregation of the platinum catalyst, etc.
  • the principle of action that can reduce or prevent defects is considered to be as follows.
  • the platinum catalyst of the present disclosure is intended to be a platinum complex represented by the following formula 1 in which 1,3-divinyltetramethyldisiloxane is coordinated with respect to platinum:
  • 1,3-divinyltetramethyldisiloxane is coordinated with respect to platinum, which causes steric hindrance and suppresses aggregation of the platinum catalyst as compared with platinum having no ligand. can do.
  • a platinum catalyst having such a ligand is mixed with a high-viscosity silicone oil, for example, if it is not stored in a cool and dark place with nitrogen purge, the platinum catalyst will aggregate and turn black. Resulting in. Aggregation of the platinum catalyst leads to an increase in the particle size of the platinum catalyst, that is, a decrease in the surface area, which may cause a decrease in the catalytic activity.
  • 1,3-divinyltetramethyldisiloxane which is a ligand, becomes easy to be attached to and detached from platinum because its thermal motion becomes active as the temperature rises.
  • the surface of platinum tends to be temporarily exposed, and when it comes into contact with adjacent platinum, it tends to aggregate, so it is considered that blackening progresses especially at high temperatures.
  • the present inventor has added a predetermined amount of a platinum catalyst to the first unsaturated organopoly, even in the case of an oil-in-water emulsified composition which is a water-containing system, which is generally said to have worse storage stability. Surprisingly, it was found that the storage stability of the platinum catalyst at high temperatures was improved when it was added to the oil phase together with siloxane.
  • the first unsaturated organopolysiloxane which is simultaneously blended in the oil phase, also has the ability to coordinate with platinum. Therefore, even if 1,3-divinyltetramethyldisiloxane deviates from platinum as the temperature rises, the first unsaturated organopolysiloxane complements the site and suppresses the progress of aggregation of the platinum catalyst. It is thought that it can be done.
  • the fact that the oil phase is dispersed in the form of fine emulsified particles (oil droplets) is considered to be one of the factors that suppress the progress of aggregation of the platinum catalyst. ing. That is, even if the complementary action of the first unsaturated organopolysiloxane occurs, the newly coordinated first unsaturated organopolysiloxane is also detached from the platinum catalyst by thermal motion, so that the surface of platinum is exposed. Can be. In the case of a single phase containing only an oil phase, since the oil phase in which the platinum catalyst is present is a continuous phase, it is considered that there is a relatively high possibility that platinum having a bare surface comes into contact with each other.
  • the oil phase is dispersed in the form of emulsified particles, and is separated from the platinum catalyst in other emulsified particles via the aqueous phase.
  • the possibility of platinum having bare surfaces coming into contact with each other is lower than in the case of a single phase containing only an oil phase.
  • the complementary action of the predetermined amount of the first unsaturated organopolysiloxane blended in the oil phase and the separating action of the platinum catalyst by the emulsified particles are synergistic. Therefore, it is thought that the storage stability of the platinum catalyst at high temperatures can be improved. Needless to say, if the storage stability at a high temperature is excellent, the storage stability at a low temperature is more excellent than that.
  • high temperature can be intended to be 50 ° C. or higher, 60 ° C. or higher, or 70 ° C. or higher, and 90 ° C. or lower, 85 ° C. or lower, or 80 ° C. or lower.
  • viscosity refers to a measure of the resistance of a fluid being deformed by either shear stress or tensile stress.
  • the viscosities of the first and second agents in an artificial skin forming agent affect the thickness, spreadability, and uniformity and / or uniformity of the layers formed on the substrate.
  • Viscosity is dynamic viscosity (also known as absolute viscosity, typical units are Pa ⁇ s, Poise, P, cP) or kinematic viscosity (typical units are cm 2 / s, Stoke, St, It can be reported as any of cst), and this kinematic viscosity is the dynamic viscosity divided by the density of the measured fluid.
  • the viscosity range of the components disclosed herein is generally a unit of kinematic viscosity (eg,) as measured by the supplier of each component using a leometer or a Canon-Fenske tube viscometer. , Cst), but the viscosity of the fluid may be, for example, a leometer (eg, a linear shear leometer or a dynamic shear leometer) or a viscometer (viscosity meter, eg, a capillary viscometer or a rotational viscometer). It can also be measured using (called).
  • a leometer eg, a linear shear leometer or a dynamic shear leometer
  • viscometer viscosity meter, eg, a capillary viscometer or a rotational viscometer
  • crosslinking in the present disclosure also includes the concept generally referred to as “curing”.
  • body surface means the skin surface of the body.
  • Oil-in-water emulsification composition >> The oil-in-water emulsified composition containing the platinum catalyst of the present disclosure (sometimes referred to simply as "composition") is excellent in storage stability of the platinum catalyst at high temperatures.
  • compositions of the present disclosure are selected from at least one temperature selected from 50 ° C, 60 ° C, and 70 ° C, and from 8 hours, 1 day, 7 days, and 14 days.
  • a D rating, a C rating, a B rating, or an A rating can be obtained in a storage stability test described later for at least one period.
  • the oil-in-water emulsified composition of the present disclosure is 5,000 cst or more immediately after preparation of the composition, for example, from the viewpoint of usability, emulsification stability, storage stability of platinum catalyst, and the like. It can be 6,000 cst or more, 7,000 cst or more, or 8,000 cst or more.
  • the upper limit of the viscosity is not particularly limited and may be, for example, 20,000 cst or less, 18,000 cst or less, or 15,000 cst or less.
  • the viscosity is a value measured with a B-type viscometer (Bismetron manufactured by Shibaura System Co., Ltd.) at 25 ° C. and 12 rotations / minute (rotor No. 3 or No. 4) for 60 seconds.
  • the dispersion medium in the oil-in-water emulsified composition of the present disclosure contains water.
  • the amount of water to be blended is not particularly limited. For example, from the viewpoint of usability, emulsion stability, storage stability of platinum catalyst, etc., 15% by mass or more, 20% by mass or more, and 30% by mass with respect to the total amount of the composition. % Or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 70% by mass or more, or 80% by mass or more, and 90% by mass or less, 80% by mass or less, 70% by mass or less. , 60% by mass or less, or 50% by mass or less.
  • the water that can be used in the oil-in-water emulsified composition of the present disclosure is not particularly limited, but water used for cosmetics, quasi-drugs, etc. can be used.
  • water used for cosmetics, quasi-drugs, etc. can be used.
  • ion-exchanged water, distilled water, ultrapure water, tap water and the like can be used.
  • oil droplets as an oil phase or a dispersed phase in an oil-in-water emulsified composition contain an oil component, an emulsifier, and a catalyst.
  • the blending amount of the oil is not particularly limited, and for example, from the viewpoint of usability, emulsion stability, storage stability of the platinum catalyst, etc., 1% by mass or more, 3% by mass or more, and 5% by mass with respect to the total amount of the composition. % Or more, 10% by mass or more, 15% by mass or more, or 20% by mass or more, and 50% by mass or less, 40% by mass or less, 30% by mass or less, 20% by mass or less, 15% by mass or less. , Or 10% by mass or less.
  • the oil content is not particularly limited, and examples thereof include liquid fats and oils, solid fats and oils, waxes, hydrocarbon oils, silicone oils, and polar oils.
  • the oil content can be used alone or in combination of two or more.
  • silicone oil is preferable from the viewpoint of compatibility with 1,3-divinyltetramethyldisiloxane, which is coordinated with the catalyst blended in the oil droplets.
  • the ratio of silicone oil in the oil content is not particularly limited, and is, for example, 50% by mass or more, 60% by mass or more, 70% by mass or more, 80% by mass or more, or 90% by mass or more with respect to the total amount of oil content. Is preferable.
  • the upper limit of such a ratio is not particularly limited, but may be, for example, 100% by mass or less, less than 100% by mass, 98% by mass or less, or 95% by mass or less.
  • composition of the present disclosure contains, as an oil component, a first unsaturated organopolysiloxane which is a kind of silicone oil.
  • the first unsaturated organopolysiloxane also has a function as a dispersant for a platinum catalyst.
  • the first unsaturated organopolysiloxane is not particularly limited as long as it has the ability to improve the storage stability of the catalyst.
  • an organopolysiloxane having a vinyl group, a vinyl-terminated organopolysiloxane, and a vinylized organopolysiloxane At least one unsaturated organopolysiloxane selected from organopolysiloxanes having a branched chain can be used.
  • vinyl-terminated polydimethylsiloxane vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer
  • vinyl-terminated polyphenylmethylsiloxane vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer
  • vinyl-terminated trifluoropropylmethylsiloxane- vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoropropylmethylsiloxane-.
  • Dimethylsiloxane Polymer Vinyl-Terminated diethylsiloxane-Dimethylsiloxane Polymeric, Vinylmethylsiloxane-Dimethylsiloxane Polymeri, trimethylsiloxy-Terminated Vinylmethylsiloxane-Dimethylsiloxane Polymeric, Cyranol-Terminated Vinylmethylsiloxane-Dimethylsiloxane Polymericator, Vinylmethylsiloxane Homopolymer, Vinyl T -Structural polymers, vinyl Q-structural polymers, monovinyl-terminated polydimethylsiloxanes, vinylmethylsiloxane terpolymers, and vinylmethoxysilane homopolymers can be mentioned.
  • the first unsaturated organopolysiloxane can be used alone or in combination of two or more.
  • vinyl-terminated polydimethylsiloxane is preferable, and divinyldimethicone and 1,3-divinyltetramethyldisiloxane are more preferable, from the viewpoint of the complementing performance of the ligand to the catalyst and the storage stability of the catalyst.
  • the term "end” is intended to be either one end or both ends. When distinguishing these, for example, it can be expressed as "vinyl single end" or "vinyl both ends".
  • the first unsaturated organopolysiloxane is contained so that the mass ratio of the first unsaturated organopolysiloxane to the total amount of platinum in the platinum complex described later is 200 or more. ..
  • the mass ratio is preferably 230 or more, 250 or more, 270 or more, 300 or more, 350 or more, 400 or more, 450 or more, or 500 or more.
  • the upper limit of the mass ratio is not particularly limited, but may be, for example, 2,000 or less, 1,500 or less, 1,000 or less, 900 or less, 800 or less, 700 or less, 600 or less, or 500 or less. can.
  • the portion thereof is designated as the first unsaturated organopolysiloxane.
  • the storage stability of the catalyst under high temperature can be improved.
  • the mixing ratio of the first unsaturated organopolysiloxane in the oil is, for example, 50% by mass or more with respect to the total amount of the oil from the viewpoint of the complementing performance of the ligand to the catalyst and the storage stability of the catalyst. , 60% by mass or more, 70% by mass or more, 80% by mass or more, or 90% by mass or more.
  • the upper limit of such a ratio is not particularly limited, but may be, for example, 100% by mass or less, less than 100% by mass, 98% by mass or less, or 95% by mass or less.
  • the size of the first unsaturated organopolysiloxane can be indirectly specified by the viscosity. That is, it can be said that if the viscosity is small, the size is also small, and if the viscosity is large, the size is also large.
  • the viscosity of the first unsaturated organopolysiloxane at 25 ° C. is less than 1,000 cst, 700 cst or less, 500 cst or less, or 300 cst or less from the viewpoint of the complementing performance of the ligand to the catalyst and the storage stability of the catalyst. It is preferably 50 cst or more, 100 cst or more, or 150 cst or more.
  • the viscosity is a value measured with a B-type viscometer (Bismetron manufactured by Shibaura System Co., Ltd.) at 25 ° C. and 12 rotations / minute (rotor No. 3 or No. 4) for 60 seconds.
  • the first unsaturated organopolysiloxane having a viscosity of less than 1,000 cst When such a first unsaturated organopolysiloxane having a viscosity of less than 1,000 cst is used, the first unsaturated organopolysiloxane having a viscosity of less than 1,000 cst with respect to the total amount of platinum in the platinum complex is used.
  • the mass ratio is preferably more than 150, 155 or more, 160 or more, 180 or more, 200 or more, 230 or more, 250 or more, 270 or more, 300 or more, 350 or more, 400 or more, 450 or more, or 500 or more.
  • the upper limit of the mass ratio is not particularly limited, but may be, for example, 2,000 or less, 1,500 or less, 1,000 or less, 900 or less, 800 or less, 700 or less, 600 or less, or 500 or less. can.
  • the first unsaturated organopolysiloxane it is preferable to use an unsaturated organopolysiloxane having a viscosity at 25 ° C. of 50 cst or more and less than 1,000 cst.
  • an unsaturated organopolysiloxane having a viscosity at 25 ° C. of less than 50 cst is used.
  • Saturated organopolysiloxane and / or unsaturated organopolysiloxane of 1,000 cst or more may be used or used in combination.
  • the blending ratio of the unsaturated organopolysiloxane of 50 cst or more and less than 1,000 cst in the first unsaturated organopolysiloxane is, for example, 30 with respect to the total amount of the first unsaturated organopolysiloxane. It can be mass% or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 70% by mass or more, or 80% by mass or more, and less than 100% by mass, 98% by mass or less, or 95% by mass. It can be less than or equal to%.
  • the silicone oils other than the first unsaturated organopolysiloxane are not particularly limited, and for example, chain silicones such as dimethylpolysiloxane (dimethicone), methylphenylpolysiloxane, and methylhydrogenpolysiloxane; Cyclic silicones such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexasiloxane can be used.
  • Other silicone oils can be used alone or in combination of two or more.
  • the emulsifier in the present disclosure is intended to be an agent having an emulsifying function (surfactant ability), and may also include an agent generally referred to as a surfactant.
  • the amount of the emulsifier to be blended is not particularly limited.
  • emulsifier for example, anionic, cationic, amphoteric, or nonionic emulsifiers can be used.
  • the emulsifier can be used alone or in combination of two or more.
  • polymer emulsifiers are preferable from the viewpoint of storage stability of the platinum catalyst.
  • the polymer emulsifier can typically be intended as an emulsifier (surfactant) having a large molecular weight and a low emulsifying ability as compared with a general emulsifier (surfactant).
  • an emulsifier having a high emulsifying ability is generally used.
  • the present inventor finds that the use of a polymer emulsifier having a relatively low emulsifying ability is even more excellent in the storage stability of the platinum catalyst. I found.
  • the effect of further improving the storage stability of the platinum catalyst by using the polymer emulsifier is considered as follows.
  • a general emulsifier (surfactant) having a high emulsifying ability other than a polymer emulsifier is used, the emulsified particles become finer, so that the emulsified composition is usually stabilized.
  • 1,3-divinyltetramethyldisiloxane is coordinated on the surface of the catalyst.
  • the emulsifier having a high emulsifying ability acts to pull out the platinum catalyst from the oil phase to the aqueous phase, so that the platinum catalyst moved to the aqueous phase side becomes unstable, aggregates, and becomes easy to blacken. thinking.
  • the polymer emulsifier having a low emulsifying ability can stably store the platinum catalyst in the oil phase because the pulling action of the platinum catalyst into the aqueous phase is weak.
  • the weight average molecular weight of the polymer emulsifier can be 500 or more, 700 or more, 1,000 or more, 1,500 or more, or 2,000 or more from the viewpoint of emulsion stability, storage stability of the platinum catalyst, and the like. ..
  • the upper limit of the weight average molecular weight of the polymer emulsifier is not particularly limited, and may be, for example, 1,000,000 or less, 100,000 or less, 10,000 or less, or 5,000 or less.
  • dissolve the emulsifier in N, N-dimethylformamide (DMF) dissolve the emulsifier in N, N-dimethylformamide (DMF) to prepare a 0.5% solution, and use this to prepare a 0.5% solution by GPC (gel permeation chromatography) under the following conditions.
  • DMF N, N-dimethylformamide
  • the polymer emulsifier is not particularly limited, and is, for example, (Acrylate / alkyl acrylate (C10-30)) crosspolymer, (acryloyldimethyltaurineammonium / behenes-25 methacrylate) crosspolymer, (hydroxyethyl acrylate / acryloyldimethyl).
  • At least one selected from taurine Na) copolymer, PEG-modified crosspolymer / copolymer siloxane, polyether-modified crosspolymer / copolymer siloxane, and polyoxyethylene can be mentioned.
  • (Acrylate / alkyl acrylate (C10-30)) crosspolymer is preferable from the viewpoint of emulsion stability, storage stability of platinum catalyst and the like.
  • the amount of general emulsifiers (surfactants) other than polymer emulsifiers (surfactants), especially silicone emulsifiers is small from the viewpoint of storage stability of the platinum catalyst.
  • the blending amount of such an emulsifier is, for example, less than 1% by mass, 0.7% by mass or less, 0.5% by mass or less, 0.3% by mass or less, or 0.1 by mass with respect to the total amount of the composition. It is preferably not more than% by mass, and it is more preferable that such an emulsifier is not contained in the composition.
  • the weight average molecular weight of general emulsifiers (surfactants) other than polymer emulsifiers can be less than 500, 450 or less, or 400 or less, and 100 or more, 150 or more, or 200 or more. Can be done.
  • the HLB of a general emulsifier (surfactant) other than a polymer emulsifier can be 2.0 or more, 3.0 or more, or 4.0 or more, and 10.0 or less, 9.0. It can be less than or equal to or less than 8.0.
  • the emulsified composition of the present disclosure contains, as a catalyst, at least a platinum complex coordinated with 1,3-divinyltetramethyldisiloxane represented by the following formula 1.
  • the content of the platinum complex is not particularly limited, and is 0.01% by mass or more, 0.05% by mass or more, 0.10% by mass or more, 0.15% by mass or more, or 0.15% by mass or more, based on the total amount of the composition. It can be 0.20% by mass or more.
  • the upper limit of the content is not particularly limited, and is 3.0% by mass or less, 2.5% by mass or less, 2.0% by mass or less, 1.5% by mass or less, 1.0% by mass or less, 0.70. It can be mass% or less, 0.50 mass% or less, or 0.30 mass% or less.
  • the content of platinum itself in the platinum complex is not particularly limited, and is 0.001% by mass or more, 0.005% by mass or more, 0.010% by mass or more, and 0.015% by mass with respect to the total amount of the composition.
  • the above, or 0.020% by mass or more can be used.
  • the upper limit of the content is not particularly limited and may be 1.0% by mass or less, 0.50% by mass or less, 0.10% by mass or less, or 0.050% by mass or less.
  • the emulsified composition of the present disclosure may contain other catalysts in addition to the above-mentioned platinum complex as long as the effects of the present disclosure are not affected.
  • catalysts examples include Group VIII metal catalysts, such as platinum catalysts other than the platinum complex, rhodium catalysts, palladium catalysts, cobalt catalysts, nickel catalysts, ruthenium catalysts, osmium catalysts, and iridium catalysts, and IVA.
  • Group metal catalysts such as germanium catalysts and tin catalysts can be mentioned.
  • Other catalysts can be used alone or in combination of two or more.
  • platinum catalysts other than the platinum complex include platinum carbonylcyclovinylmethylsiloxane complex, platinumcyclovinylmethylsiloxane complex, platinum octanealdehyde / octanol complex, and other Pt (0) catalysts, such as Karlstead catalyst.
  • Platinum-alcohol complex platinum-alkoxide complex, platinum-ether complex, platinum-aldehyde complex, platinum-ketone complex, platinum-halogen complex, platinum-sulfur complex, platinum-nitrogen complex, platinum-phosphorus complex, platinum-carbon double Bonded complex, platinum carbon triple bond complex, platinum-imide complex, platinum-amide complex, platinum-ester complex, platinum-phosphate ester complex, platinum-thiol ester complex, platinum isolated electron pair complex, platinum-aromatic complex, platinum ⁇ -Electronic complexes and combinations thereof can be mentioned.
  • rhodium catalyst examples include tris trichloride (dibutyl sulfide) rhodium and rhodium trichloride hydrate.
  • tin catalyst examples include tin octanoate (II), tin neodecanoate (II), dibutyltin diisooctylmaleate, di-n-butylbis (2,4-pentandionate) tin, and di-n-butylbutoxy. Included are chlorotin, dibutyltin dilaurate, dimethyltin dineodecanoate, dimethylhydroxy (oleate) tin, and tin oleate (II).
  • the blending amount of the catalyst other than the platinum complex may be less than 50% by mass, 30% by mass or less, 10% by mass or less, 5% by mass or less, or 1% by mass or less with respect to the total amount of the catalyst. .. From the viewpoint of emulsion stability, storage stability of the platinum catalyst, etc., it is preferable that other catalysts are not contained in the emulsified composition.
  • the oil-in-water emulsified composition of the present disclosure may appropriately contain various components as long as it does not affect the effects of the present disclosure.
  • Such optional components include, for example, moisturizing agents, emollients, thickeners, water-soluble polymers, oil-soluble polymers, film-forming agents such as siliconeized polysaccharides, higher fatty acids such as isostearic acid, and metal ion sequestering agents.
  • Lower alcohols such as ethanol, higher alcohols such as stearyl alcohol, polyhydric alcohols such as 1,3-butylene glycol, various extracts, sugars, amino acids, organic amines, chelating agents, ultraviolet absorbers, pH adjusters, skin nutrition
  • Water-soluble agents applicable to agents, vitamins, pharmaceuticals, non-pharmaceutical products, cosmetics, etc., buffers, anti-fading agents, preservatives, propellants, organic powders, pigments, dyes, pigments, fragrances, etc. can.
  • the optional ingredients can be used alone or in combination of two or more.
  • the oil-in-water emulsified composition of the present disclosure described above can be used for various purposes. Although not limited to the following uses, the oil-in-water emulsified composition of the present disclosure has excellent storage stability of the platinum catalyst, and can reduce or suppress defects such as discoloration, so that it is possible to prevent changes in color tone. It can be suitably used as a second agent of an artificial skin forming agent containing a first agent and a second agent, for example, in a desired application. Such an artificial skin forming agent is obtained, for example, by applying the first agent to the body surface to form the first agent layer and then applying the second agent to the first agent layer to crosslink the first agent layer. Artificial skin can be formed.
  • the application performance of the artificial skin forming agent can be evaluated by the viscosity using a B-type viscometer (Shibaura System Co., Ltd., Bismetron).
  • the viscosities of the first and second agents of the artificial skin forming agent of the present disclosure measured under the conditions of 25 ° C. and 60 rotations / minute (rotor No. 3 or No. 4) immediately after preparation are, for example, 100 mPa ⁇ s or more.
  • 500 mPa ⁇ s or more, 1,000 mPa ⁇ s or more, 2,000 mPa ⁇ s or more, 5,000 mPa ⁇ s or more, 7,500 mPa ⁇ s or more, 10,000 mPa ⁇ s or more, or 15,000 mPa ⁇ s or more Can be 1,000,000 mPa ⁇ s or less, 750,000 mPa ⁇ s or less, 500,000 mPa ⁇ s or less, 250,000 mPa ⁇ s or less, 200,000 mPa ⁇ s or less, 175,000 mPa ⁇ s or less, 150, It can be 000 mPa ⁇ s or less, 125,000 mPa ⁇ s or less, 100,000 mPa ⁇ s or less, or 80,000 mPa ⁇ s or less.
  • the artificial skin forming agent has a viscosity of 20,000 mPa ⁇ s or less, 15,000 mPa ⁇ s or less, or 10,000 mPa ⁇ s or less from the viewpoint of smooth application performance and suppression of dripping from the skin. It is preferable to have a viscosity of 3,000 mPa ⁇ s or more, 5,000 mPa ⁇ s or more, or 7,000 mPa ⁇ s or more.
  • the viscosities of the first agent and the second agent in the artificial skin forming agent of the present disclosure measured under the conditions of 25 ° C. and 60 rpm (rotor No. 3) after 2 weeks are determined. From the viewpoint of smooth application performance and suppression of dripping from the skin, it is preferably 50,000 mPa ⁇ s or less, 30,000 mPa ⁇ s or less, or 15,000 mPa ⁇ s or less, preferably 5,000 mPa ⁇ s or more. It is preferably 7,000 mPa ⁇ s or more, or 10,000 mPa ⁇ s or more.
  • the film performance of the artificial skin can be evaluated, for example, by the presence or absence of tearing of the artificial skin when peeled from the skin. For example, when the tearing of the applied artificial skin is 15% or less, 10% or less, or 5% or less of the whole, it can be said that the film performance is excellent.
  • the lower limit of tearing is not particularly limited, but may be, for example, 0% or more or more than 0%.
  • the film performance can be evaluated based on the tensile strength and elongation at break, which will be described later.
  • the first agent constituting the artificial skin forming agent of the present disclosure contains a second unsaturated organopolysiloxane and a hydride-functionalized polysiloxane.
  • the first agent may be, for example, in the form of an anhydrous form, or may be in the form of an oil-in-water type or a water-in-oil type emulsion, but the drying property after the first agent is applied to the body surface. From the viewpoint of crosslinkability and the like, it is advantageous that the first agent is in an anhydrous form.
  • anhydrous form usually does not require a preservative against bacteria or mold, so it can be stored for a longer period of time than an emulsion with similar components.
  • anhydrous means that the composition does not contain water, and the content of water is low, that is, 10% by mass or less, 5% by mass or less. It is also intended to be 2% by mass or less, 1% by mass or less, or 0.1% by mass or less.
  • the first agent is applied to the body surface by coating or the like, it is preferable to have a glass transition temperature equal to or lower than the body temperature from the viewpoint of coating performance.
  • the glass transition temperature can be 37 ° C. or lower, 25 ° C. or lower, 10 ° C. or lower, or 0 ° C. or lower.
  • the lower limit of the glass transition temperature is not particularly limited, but may be, for example, ⁇ 30 ° C. or higher, ⁇ 20 ° C. or higher, or ⁇ 10 ° C. or higher.
  • the "glass transition temperature” refers to the temperature at which the transition from the solid state to the liquid state occurs, and can be measured using, for example, a differential scanning calorimeter (DSC) compliant with ASTM D3418-03.
  • DSC differential scanning calorimeter
  • the second unsaturated organopolysiloxane is not particularly limited, and examples thereof include one or more organopolysiloxanes having at least two carbon-carbon double bonds or at least one carbon-carbon triple bond in the molecule. can.
  • the second unsaturated organopolysiloxane is preferably one or more organopolysiloxanes having at least two alkenyl functional groups on average and a viscosity of 10,000-2,000,000 cst at 25 ° C. be able to.
  • "carbon-carbon double bond” and “carbon-carbon triple bond” may be simply referred to as "double bond” and "triple bond".
  • the second unsaturated organopolysiloxane can be used alone or in combination of two or more.
  • Such organopolysiloxanes may contain double or triple bonds in the terminal units of the polymer, in the non-terminal monomer units of the polymer, or in combinations thereof, among others, in the non-terminal monomer units of the polymer. Is preferable.
  • the double bond-containing monomer units in the organopolysiloxane averaged 40 monomer units or more, 200 monomer units or more, 400 monomer units or more, 1,000 monomer units or more, or 2,000 monomer units. It may be separated by more than that.
  • the amount of double or triple bond containing monomer units of an organopolysiloxane having a double or triple bond can be, for example, 0.01% by weight or more or 0.03% by weight or more. , 2% by mass or less or 0.6% by mass or less.
  • the vinyl equivalent of the organopolysiloxane having a double or triple bond can be, for example, 0.005 or more or 0.01 or more per kilogram, 0.5 or less or 0.25. It can be:
  • the approximate molar amount of double or triple bonds in an organopolysiloxane can be calculated based on the average molecular weight of the organopolysiloxane.
  • the average molecular weight or molecular mass of each component in the artificial skin-forming agent disclosed herein is generally provided by the supplier of each component and is in units of dalton (Da) or equivalent g / mol. Can be represented.
  • the second unsaturated organopolysiloxane can have a viscosity of 10,000-2,000,000 cst at 25 ° C.
  • the lower limit of the viscosity is preferably 20,000 cst or more, 40,000 cst or more, 60,000 cst or more, 80,000 cst or more, or 100,000 cst or more, and 125,000 cst or more or 150,000 cst or more. Is more preferable.
  • the upper limit of the viscosity is preferably 1,000,000 cst or less, 500,000 cst or less, 450,000 cst or less, 400,000 cst or less, 350,000 cst or less, 300,000 cst or less, or 250,000 cst or less. It is more preferably 200,000 cst or less or 180,000 cst or less, and further preferably 165,000 cst or less.
  • the second unsaturated organopolysiloxane can have an average molecular weight of 60,000 Da to 500,000 Da.
  • the lower limit of the average molecular weight is preferably 72,000 Da or more, 84,000 Da or more, 96,000 Da or more, or 100,000 Da or more, and more preferably 140,000 Da or more or 150,000 Da or more. ..
  • the upper limit of the average molecular weight is preferably 200,000 Da or less, 190,000 Da or less, 180,000 Da, or 170,000 Da or less, more preferably 160,000 Da or less, and further preferably 155,000 Da or less. preferable.
  • the second unsaturated organopolysiloxane for example, at least one selected from an organopolysiloxane having a vinyl group, a vinyl-terminated organopolysiloxane, and an organopolysiloxane having a vinylized branched chain is mentioned. Can be done.
  • Such a second unsaturated organopolysiloxane include vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, and vinylphenylmethyl-terminated vinylphenylsiloxane.
  • -Phenylmethylsiloxane copolymer vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, silanol-terminated vinylmethyl At least one selected from a siloxane-dimethylsiloxane copolymer, a vinylmethylsiloxane homopolymer, a vinyl T-structure polymer, a monovinyl-terminated polydimethylsiloxane, a vinylmethylsiloxane tarpolymer, and a vinylmethoxysilane homopolymer can be employed.
  • vinyl-terminated polydimethylsiloxane is preferable, and
  • the blending amount of the second unsaturated organopolysiloxane in the first agent may be appropriately adjusted according to the required coating performance and the like, and is not particularly limited.
  • the blending amount of the second unsaturated organopolysiloxane is 5% by mass or more, 10% by mass or more, 20% by mass or more, 30% by mass or more, 35% by mass or more, or 40 with respect to the entire first agent. It can be 90% by mass or less, 80% by mass or less, 70% by mass or less, 60% by mass or less, 50% by mass or less, or 45% by mass or less.
  • Hydride-functionalized polysiloxane is not particularly limited, and examples thereof include compounds of the following formula 2. Hydride-functionalized polysiloxanes can be used alone or in combination of two or more:
  • R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are independently hydrogen, C 1-20 alkyl and C 2 respectively. Selected from -20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy, m and n are independently integers from 10 to 6000. However, at least one of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b is hydrogen.
  • At least one of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b is hydrogen and the rest is C 1- . It is 20 alkyl.
  • At least two of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are hydrogen (eg, functionalized hydrides). 2 Si—H units per polysiloxane molecule).
  • R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are hydrogen (eg, a functionalized hydride polysiloxane molecule). 3 Si—H units per unit).
  • At least two of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are hydrogen (eg, functionalized hydride polysiloxane). 2 Si—H units per molecule), with the rest being C 1-20 alkyl.
  • R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are hydrogen (eg, a functionalized hydride polysiloxane molecule). 3 per Si—H unit), the rest are C 1-20 alkyl.
  • At least two of R 4b , R 5b , R 9b and R 10b are hydrogen (eg, two Si—H units per functionalized hydride polysiloxane molecule) and the rest are C 1- . It is 20 alkyl.
  • At least three of R 4b , R 5b , R 9b and R 10b are hydrogen (eg, 3 Si—H units per functionalized hydride polysiloxane molecule) and the rest are C 1-20 . It is alkyl.
  • the sum of m and n is 10-1,300, 10-1,100, 10-600, 15-500, 15-400, 20-300, 20-200, 25-100, It is an integer of 25 to 75, 30 to 50, or 40 to 45.
  • the hydride-functionalized polysiloxane can include a non-terminal and / or terminally hydroxylated organopolysiloxane, and one or more having at least two Si—H units in the molecule.
  • a non-terminal and / or terminally hydroxylated organopolysiloxane can be mentioned, preferably, one or more organopolysiloxanes composed of the organopolysiloxanes of the above, preferably having at least two Si—H units on average and having a viscosity of 2 to 100,000 cst at 25 ° C.
  • the organopolysiloxane having Si—H units may contain such Si—H units in the terminal units of the polymer, in the non-terminal monomer units of the polymer, or in combinations thereof.
  • the Si—H unit is preferably contained in the non-terminal monomer unit of the polymer.
  • the hydride-functionalized polysiloxane in this case may be alkyl-terminated.
  • R 2b and R 7b may be C 1-20 alkyl.
  • R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl. May be.
  • R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b and R 10b are C 1-20 alkyl, eg, C 1 alkyl (eg, methyl), respectively.
  • R 9b may be hydrogen.
  • R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b and R 9b are C 1-20 alkyl, eg, C 1 alkyl (eg, methyl), respectively.
  • R 10b may be hydrogen.
  • the Si—H-containing monomer unit in the organopolysiloxane averages 1 monomer unit or more, 2 monomer units or more, 5 monomer units or more, 10 monomer units or more, 20 monomer units or more, and 40 monomer units. As mentioned above, it may be separated by 200 monomer units or more, 400 monomer units or more, 1,000 monomer units or more, or 2,000 monomer units or more.
  • the Si—H-containing monomer unit amount of the organopolysiloxane having Si—H units is 0.003% by mass or more, 0.01% by mass or more, 0.1% by mass or more, and 1% by mass or more. It can be 3% by mass or more, 5% by mass or more, 10% by mass or more, 20% by mass or more, or 26% by mass or more, and 50% by mass or less, 45% by mass or less, 40% by mass or less, 35% by mass. % Or less, 30% by mass or less, or 27% by mass or less.
  • the Si—H content of the organopolysiloxane having the Si—H unit is 0.1 mmol / g or more, 0.5 mmol / g or more, 1 mmol / g or more, 2 mmol / g or more, 3 mmol / g or more. , Or 4 mmol / g or more, 20 mmol / g or less, 10 mmol / g or less, 9 mmol / g or less, 8 mmol / g or less, 7 mmol / g or less, 6 mmol / g or less, or 5 mmol / g or less. Can be done.
  • the approximate molar amount of Si—H units in the organopolysiloxane can be calculated based on the average molecular weight of the organopolysiloxane.
  • the hydride functionalized polysiloxane can have a viscosity of 2 to 500,000 cst at 25 ° C.
  • the lower limit of the viscosity is preferably 3 cst or more, 4 cst or more, 5 cst or more, 10 cst or more, 12 cst or more, 15 cst or more, 20 cst or more, 25 cst or more, or 30 cst or more, and more preferably 40 cst or more.
  • the upper limit of the viscosity shall be 200,000 cst or less, 100,000 cst or less, 50,000 cst or less, 20,000 cst or less, 10,000 cst or less, 5,000 cst or less, 2,000 cst or less, or 1,000 cst or less. Is preferable, and 500 cst or less is more preferable.
  • the viscosity of the hydride-functionalized polysiloxane is particularly preferably in the range of 45 to 100 cst or 45 to 50 cst at 25 ° C.
  • the hydride functionalized polysiloxane can have an average molecular weight of 400-500,000 Da.
  • the lower limit of the average molecular weight is 500 Da or more, 800 Da or more, 900 Da or more, 1,000 Da or more, 1,200 Da or more, 1,400 Da or more, 1,600 Da or more, 1,800 Da or more, 2,000 Da or more, or 2 , 200 Da or more, more preferably 2,300 Da or more.
  • the upper limit of the average molecular weight is 250,000 Da or less, 140,000 Da or less, 100,000 Da or less, 72,000 Da or less, 62,700 Da or less, 60,000 Da or less, 50,000 Da or less, 49,500 Da or less, 36, It is preferably 000 Da or less, 28,000 Da or less, 25,000 Da or less, 20,000 Da or less, 15,000 Da or less, 10,000 Da or less, 5,000 Da or less, or 4,000 Da or less, preferably 2,500 Da or less. Is more preferable.
  • Hydride-functionalized polysiloxanes are, but are not limited to, for example, hydride-terminated polydimethylsiloxanes, hydride-terminated polyphenyl- (dimethylhydrosiloxy) siloxanes, hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymers, trimethylsiloxy-terminated methyls.
  • hydrosiloxane-dimethylsiloxane copolymer polymethylhydrosiloxane
  • trimethylsiloxy-terminated polyethylhydrosiloxane triethylsiloxane
  • methylhydrosiloxane-phenyloctylmethylsiloxane copolymer methylhydrosiloxane-phenyloctylmethylsiloxane tarpolymer.
  • the blending amount of the hydride-functionalized polysiloxane in the first agent may be appropriately adjusted according to the required film performance and the like, and is not particularly limited.
  • the blending amount of the hydride-functionalized polysiloxane can be 1% by mass or more, 3% by mass or more, or 5% by mass or more, and 75% by mass or less, 60% by mass or less, based on the entire first agent. , 50% by mass or less, 40% by mass or less, 30% by mass or less, 20% by mass or less, or 10% by mass or less.
  • the first agent can optionally include other polymers.
  • Other polymers can be used alone or in combination of two or more.
  • the other polymer can have a viscosity of 0.7 cst to 50,000 cst at 25 ° C.
  • the lower limit of the viscosity is 1 cst or more, 6 cst or more, 10 cst or more, 20 cst or more, 50 cst or more, 100 cst or more, 200 cst or more, 300 cst or more, 400 cst or more, 750 cst or more, 1,000 cst or more, 1,500 cst or more, 2, It can be 000 cst or more, 2,500 cst or more, 3,000 cst or more, 3,500 cst or more, or 4000 cst or more.
  • the upper limit of the viscosity is 45,000 cst or less, 40,000 cst or less, 35,000 cst or less, 30,000 cst or less, 25,000 cst or less, 20,000 cst or less, 15,000 cst or less, 12,000 cst or less, 10,000 cst or less.
  • it can be 5,000 cst or less, 4,000 cst or less, 2,000 cst or less, 1,500 cst or less, or 1,000 cst or less.
  • the other polymer can have an average molecular weight of 180Da-80,000Da.
  • the lower limit of the average molecular weight is 500 Da or more, 800 Da or more, 1,500 Da or more, 3,000 Da or more, 6,000 Da or more, 9,400 Da or more, 10,000 Da or more, 15,000 Da or more, 20,000 Da or more, It can be 30,000 Da or more, 40,000 Da or more, 50,000 Da or more, 55,000 Da or more, 60,000 Da or more, or 62,000 Da or more.
  • the upper limit of the average molecular weight can be 75,000 Da or less, 70,000 Da or less, 65,000 Da or less, or 63,000 Da or less.
  • one or more organopolysiloxanes having at least one alkenyl functional group on average and having a viscosity of 0.7 to 50,000 cst at 25 ° C. can be mentioned.
  • vinyl-terminated polydimethylsiloxane for example, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated tori.
  • Fluoropropylmethylsiloxane-dimethylsiloxane polymer vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated vinyl rubber , Vinyl Methylsiloxane Homopolymer, Vinyl T-Structural Polymer, Vinyl Q-Structural Polymer, Unsaturated Organic Polymer (eg, Unsaturated Fat Alcohol, Unsaturated Fatty Acid, Unsaturated Fat Ester, Unsaturated Fat Amid, Unsaturated Fat Urethane, Unsaturated fatty ureas, ceramides, crosetins, lecithins
  • the blending amount of the other polymer in the first agent may be appropriately adjusted according to the required coating performance and the like, and is not particularly limited.
  • the blending amount of the other polymer may be 0.01% by mass or more, 0.1% by mass or more, 0.3% by mass or more, or 0.5% by mass or more with respect to the entire first agent. It can be 20% by mass or less, 15% by mass or less, or 10% by mass or less.
  • the molar ratio of the Si—H functional group derived from the hydride-functionalized polysiloxane to the alkenyl functional group derived from the second unsaturated organopolysiloxane is preferably 60: 1 to 1: 5. , 45: 1 to 15: 1, more preferably.
  • the molar ratio of Si—H functional groups derived from hydride-functionalized polysiloxane to alkenyl functional groups derived from other polymers is preferably 60: 1 to 1: 5, preferably 45: 1 to 45. It is more preferably 15: 1.
  • the molar ratio of the alkenyl functional group derived from the second unsaturated organopolysiloxane to the alkenyl functional group derived from the other polymer is preferably 100: 1 to 1: 100, 10: 1. It is more preferably ⁇ 1:10.
  • the oil-in-water emulsified composition of the present disclosure described above can be used as a second agent of an artificial skin forming agent.
  • the catalyst contained in such a composition can promote the cross-linking of the above-mentioned second unsaturated organopolysiloxane and hydride-functionalized polysiloxane.
  • the artificial skin forming agent of the present disclosure may contain one or more arbitrary components with respect to the first agent and / or the second agent as long as the effects of the present disclosure are not affected.
  • the optional component is not particularly limited, but for example, a feel modifier, a tackifier modifier, a spread accelerator, a diluent, an adhesion modifier, an emulsifier, an emollient agent, a surfactant, a solvent, a film forming agent, etc.
  • Emulsifiers preservatives, fibers, pigments, dyes, thickeners, protective colloids, fillers, skin permeation enhancers, optical modifiers, scatterers, adsorbents, magnetic materials, gas transport modifiers, liquids Examples include transport modifiers, pH modifiers, sensitizer modifiers, and aesthetic modifiers.
  • Fillers include, for example, carbon, silver, mica, zinc sulfide, zinc oxide, titanium dioxide, aluminum oxide, clay, chalk, talc, calculus (eg CaCO 3 ), barium sulfate, zirconium dioxide, polymer beads, silica (eg, CaCO 3).
  • silica eg, CaCO 3
  • fumed silica, silicic acid, or anhydrous silica silica aluminate
  • calcium silicate can be mentioned, which may be surface treated.
  • Such a filler can improve the physical properties (eg strength) of the coating (artificial skin) and can also serve as a viscosity modifier.
  • surface-treated silica for example, silica treated with a surface-treating agent such as hexamethyldisilazane, polydimethylsiloxane, hexadecylsilane, or methacrylsilane is preferable.
  • fumed silica is also preferable, and for example, fumed silica surface-treated with hexamethyldisilazane or the like can also be preferably used.
  • the filler can have a specific surface area of 50-500 m 2 / g.
  • the specific surface area of the filler is preferably 100 to 350 m 2 / g, more preferably 135 to 250 m 2 / g.
  • the specific surface area of the filler can be calculated using the BET method.
  • the filler can have a particle size equivalent to an area circle of 1 nm to 20 ⁇ m.
  • the particle size corresponding to the area circle of the filler is preferably 2 nm to 1 ⁇ m, and more preferably 5 nm to 50 nm.
  • the particle size equivalent to the area circle of the filler is intended to be, for example, the particle size when converted into circular particles having the same area as the projected area of the filler particles observed with a transmission electron microscope. can.
  • the particle size corresponding to the area circle can be defined as an average value of 10 or more particles.
  • the blending amount may be, for example, 1% by mass or more, 3% by mass or more, or 5% by mass or more, and 25% by mass, based on the entire first agent. Hereinafter, it can be 15% by mass or less, or 10% by mass or less.
  • the mass ratio of the total amount of the second unsaturated organopolysiloxane, hydride-functionalized polysiloxane and other polymers to the filler is 100: 1 to 1: 1. It can be preferably 50: 1 to 2: 1, more preferably 15: 1 to 3: 1, still more preferably 10: 1 to 4: 1, and particularly preferably 5. 1 to 9: 1.
  • At least one selected from pigments, dyes and fillers is preferably added to the first agent.
  • pigments and dyes when these are blended in the second agent, if this second agent is applied to the application surface of the first agent, it will harden in the middle and the pigment or dye will be formed. Color unevenness may occur because it is easy to localize. From the viewpoint of suppressing color unevenness, it is advantageous to add the pigment and the dye to the first agent.
  • the second agent may contain a pigment, a dye and a filler as long as color unevenness does not occur, but it is advantageous that these are not included in the second agent.
  • compositions of the present disclosure may further comprise one or more agents with respect to the first and / or second agent.
  • agents include cosmetics, therapeutic agents, stimulant responsive agents, and drug delivery agents.
  • Suitable cosmetic agents include, for example, moisturizers, UV absorbers, skin protectants, skin soothing agents, skin whitening agents, skin brighteners, skin softening agents, skin smoothing agents, skin bleaching agents, skin keratin removers, etc.
  • Suitable therapeutic agents include, for example, pain relievers, analgesics, antipruritic agents, anti-sciatic agents (eg, ⁇ -hydroxy acid, salicylic acid, benzoyl peroxide), anti-inflammatory agents, anti-histamine agents, corticosteroids.
  • NSAID non-steroidal anti-inflammatory drug
  • preservatives antibiotics, antibacterial agents, antifungal agents, antiviral agents, antiallergic agents, antistimulants, insect repellents, phototherapy agents, blood coagulants, anti-new
  • biopharmaceuticals include biopharmaceuticals, immune system enhancers, immune system suppressants, coaltal, anthraline, fluorinide, methotrexate, cyclosporin, pimechlorimus, tachlorimus, azathiopurine, fluorouracil, ceramide, anti-inflammatory agents, and skin cooling compounds.
  • Suitable agents include, for example, whitening agents, activators, blood circulation promoters, anti-inflammatory agents, antioxidants, enzymes, vitamins, hormones, antibacterial agents, anti-fat leak agents, amino acids and their derivatives, sugar alcohols and Examples thereof include derivatives thereof, fat-soluble agents, fat-soluble treated agents, and hair-growth agents. These can be used alone or in combination.
  • Examples of the whitening agent include hydroquinone ⁇ -D-glucose, hydroquinone ⁇ -D-glucose (arbutin), hydroquinone ⁇ -L-glucose, hydroquinone ⁇ -L-glucose, hydroquinone ⁇ -D-galactose, and hydroquinone ⁇ -D-.
  • Hydroquinone derivatives such as galactose, hydroquinone ⁇ -L-galactose, hydroquinone ⁇ -L-galactose; kodiic acid and its salts or derivatives thereof; for example L-ascorbic acid monophosphate ester, L-ascorbic acid 2-sulfate ester and the like L- Ascorbic acid monoesters, L-ascorbic acid glucosides such as L-ascorbic acid 2-glucoside, or L-ascorbic acid such as salts thereof and salts thereof or derivatives thereof; for example, tranexamic acid, dimers of tranexamic acid ( For example, trans-4- (trans-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid), an ester of tranexamic acid and hydroquinone (eg, trans-4-aminomethylcyclohexanecarboxylic acid 4'-hydroxyphenyl ester).
  • Elagic acid and its salts or derivatives thereof for example salicylic acid, 3-methoxysalicylic acid and its salts, 4-methoxysalicylic acid and its salts, 5-methoxysalicylic acid and its salts and the like salicylic acid and its salts or derivatives thereof; phenylethyl resorcinol, Examples thereof include alkyl resorcinols such as resorcin, 4-n-butylresorcinol, and resorcinol derivatives such as salts thereof; niacin and derivatives thereof such as nicotinic acid amide; nucleotides such as adenosine and guanosine or derivatives thereof, and the like.
  • activator examples include royal jelly; photosensitizer; cholesterol derivative and the like.
  • Examples of the blood circulation promoter include nonylate valenylamide; nicotinic acid benzyl ester; nicotinic acid ⁇ -butoxyethyl ester; capsaicin; zingeron; cantalistinki; ictamol; tannic acid; ⁇ -borneol; tocopherol nicotinate; inositol hexanicotinate.
  • Cicrandelate; cinnaridine; trazoline; acetylcholine derivative; verapamil; cepharanthin; ⁇ -orizanol; carbronium chloride and the like are exemplified.
  • anti-inflammatory agent examples include tranexamic acid; thiotaurine; hypotaurine; glycyrrhizinic acid derivative; glycyrrhetinic acid derivative; salicylic acid derivative; hinokitiol; zinc oxide; allantoin and the like.
  • antioxidants examples include thiotaurine; glutathione; catechin; albumin; ferritin; metallothionein and the like.
  • enzymes examples include trypsin; lysozyme chloride; chymotrypsin; semi-alkaline protectase; serrapeptase; lipase; hyaluronidase and the like.
  • vitamins examples include vitamin B6; vitamin B6 derivatives such as vitamin B6 hydrochloride; vitamin B2; vitamin B12; nicotinic acid; nicotinic acid derivatives such as nicotinic acid amide; pantotenil ethyl ether and the like.
  • hormonal agent examples include oxytocin; corticotropin; vasopressin; secretin; gastrin; calcitonin and the like.
  • antibacterial agent examples include resorcin; sulfur; salicylic acid; zinc pyrithione; photosensitive element 101; photosensitive element 102; orthovirox; hinokitiol and the like.
  • antiseborrheic agent examples include sulfur; thiantoll and the like.
  • amino acids and their derivatives include serine; methionine; tryptophan; glycine; trimethylglycine; glycylglycine; 1-piperidine propionic acid.
  • sugar alcohols and their derivatives include erythritol; xylitol; mannitol; sorbitol; inositol and the like.
  • the artificial skin forming agents of the present disclosure can be used, for example, for cosmetic or medical purposes.
  • the method of using the artificial skin forming agent of the present disclosure does not include a method of surgery, treatment or diagnosis of a human being.
  • the second agent is applied onto the first agent layer and crosslinked.
  • Method of forming artificial skin a method of applying the second agent to the body surface to form a second agent layer, then applying the first agent on the second agent layer and cross-linking to form an artificial skin.
  • a method may be mentioned in which a mixture is prepared by mixing the first agent and the second agent, and then the mixture is applied to the body surface and crosslinked to form an artificial skin. From the viewpoint of obtaining uniform artificial skin with less unevenness, such a method of use is to apply the first agent to the body surface to form the first agent layer, and then apply the second agent on the first agent layer.
  • a method of cross-linking to form an artificial skin is preferable.
  • the first agent and the second agent the above-mentioned materials and the like can be used in the same manner.
  • This method may be performed only once, but the method may be performed multiple times on the formed artificial skin.
  • the cosmetic may be applied to the body surface or artificially before the first agent, the second agent, or the mixture containing the first agent and the second agent is applied to the body surface. After forming the skin, the cosmetic may be applied to the artificial skin.
  • cosmetics for example, skin care cosmetics such as beauty essence, lotion, milky lotion, sunscreen cosmetics (sunscreen cosmetics), or makeup cosmetics such as foundation, gloss, lipstick, eye shadow, and manicure. Can be used.
  • the method of using the artificial skin forming agent of the present disclosure can also be used as a cosmetic method.
  • the "cosmetological method” is to apply the artificial skin forming agent of the present disclosure to the body surface to form artificial skin, and to beautify the condition of the body surface beautifully or to beautify the condition of the body surface. It means a method of surgery, which is different from the method of surgery, treatment or diagnosis of a human being.
  • the method of applying the first agent or the second agent to the body surface, the cosmetic application layer, or the first agent layer or the second agent layer there is no particular limitation on the method of applying the first agent or the second agent to the body surface, the cosmetic application layer, or the first agent layer or the second agent layer, and for example, a means for spreading with a finger or the like, spray application. , Transfer, etc. can be adopted.
  • the artificial skin-forming agent of the present disclosure can be applied to any part of the body on the surface of the skin, that is, on the surface of the body.
  • it can be appropriately applied to the skin surface such as face (lips, eyes, nose, cheeks, forehead, etc.), neck, ears, hands, arms, legs, legs, chest, abdomen, back and the like.
  • the skin also includes nails and the like in which the keratin of the epidermis of the skin is changed and hardened.
  • the thickness of the artificial skin prepared by using the above-mentioned artificial skin forming agent of the present disclosure is not particularly limited, and is appropriately adjusted in consideration of, for example, breathability, invisibility, compressibility, obstruction to the skin, and the like. Can be done.
  • the thickness of the artificial skin can be, for example, 0.5 ⁇ m or more, 1 ⁇ m or more, 10 ⁇ m or more, 30 ⁇ m or more, or 40 ⁇ m or more.
  • the upper limit of the thickness is not particularly limited, but may be, for example, 150 ⁇ m or less, 100 ⁇ m or less, 90 ⁇ m or less, 80 ⁇ m or less, 70 ⁇ m or less, 60 ⁇ m or less, or 50 ⁇ m or less.
  • the thickness shall be defined as an average value calculated by measuring the thickness of any part of the artificial skin 5 times using a high-precision digital micrometer (MDH-25MB, manufactured by Mitutoyo Co., Ltd.). Can be done.
  • the resulting artificial skin can exhibit good adhesion to the body surface.
  • Such adhesive strength can be evaluated by substituting the adhesive strength of artificial skin applied on the polypropylene substrate.
  • the adhesive strength of the artificial skin on the polypropylene substrate can be 2 N / m or more, 5 N / m or more, 8 N / m or more, 10 N / m or more, or 15 N / m or more.
  • the upper limit of the adhesive strength is not particularly limited, but for example, from the viewpoint of peelability from the skin, 200 N / m or less, 100 N / m or less, 80 N / m or less, 50 N / m or less, or 30 N / m. It can be as follows.
  • the adhesive strength complies with the stripping adhesion test of ASTM C794 and can be measured using an Instron device.
  • the resulting artificial skin can exhibit good tensile strength.
  • the tensile strength of the artificial skin can be 0.05 MPa or more, 0.10 MPa or more, 0.20 MPa or more, or 0.50 MPa or more.
  • the upper limit of the tensile strength is not particularly limited, but may be, for example, 5.0 MPa or less, 3.0 MPa or less, 2.0 MPa or less, or 1.0 MPa or less.
  • the tensile strength is based on the tensile tensile test of ASTM D5083 and can be measured using an Instron device.
  • the resulting artificial skin is capable of exhibiting good breaking elongation.
  • the breaking elongation of the artificial skin can be 25% or more, 50% or more, 100% or more, 200% or more, or 400% or more.
  • the upper limit of the elongation at break is not particularly limited, but may be, for example, 1,500% or less, 1,200% or less, 1,000% or less, 800% or less, or 600% or less.
  • the elongation at break is based on the tensile tensile test of ASTM D5083 and can be measured using an Instron device.
  • the resulting artificial skin can exhibit good oxygen permeability.
  • the oxygen permeability of the artificial skin is 5 ⁇ 10 -9 cm 3 / (cm 2 ⁇ s) or more, or 5 ⁇ 10 -7 cm 3 / (cm 2 ⁇ s) or more, or in the artificial skin with a thickness of 300 ⁇ m. It is possible to achieve 5 ⁇ 10-5 cm 3 / (cm 2 ⁇ s) or more.
  • the upper limit of the oxygen permeability is not particularly limited, but for example, 5 cm 3 / (cm 2 ⁇ s) or less, 0.5 cm 3 / (cm 2 ⁇ s) or less, 5 ⁇ 10 ⁇ 2 cm 3 / (cm).
  • the oxygen permeability can be measured using a Mocon device in accordance with the oxygen gas permeability test of the plastic film and sheet of ASTM F2622.
  • the resulting artificial skin can exhibit good water vapor permeability.
  • the water vapor permeability of the artificial skin is 1 ⁇ 10 -9 cm 3 / (cm 2 ⁇ s) or more, 1 ⁇ 10 -8 cm 3 / (cm 2 ⁇ s) or more, or 1 ⁇ 10 -9 cm 3 / (cm 2 ⁇ s) or more in the artificial skin having a thickness of 300 ⁇ m. It is possible to achieve 1 ⁇ 10-7 cm 3 / (cm 2 ⁇ s) or more.
  • the upper limit of the water vapor permeability is not particularly limited, but for example, 1.5 ⁇ 10 -1 cm 3 / (cm 2 ⁇ s) or less, 1.5 ⁇ 10 ⁇ 2 cm 3 / (cm 2 ⁇ s). Below, 1 ⁇ 10 -4 cm 3 / (cm 2 ⁇ s) or less, 1 ⁇ 10 -5 cm 3 / (cm 2 ⁇ s) or less, or 1 ⁇ 10 -6 cm 3 / (cm 2 ⁇ s) or less. Can be.
  • the water vapor permeability can be measured using a Mocon device in accordance with the water vapor permeability test of the plastic film and sheet of ASTM F1249.
  • kits with artificial skin forming agent can be provided as a kit having the first agent and the second agent constituting such a composition.
  • the kit may include, for example, a member for facilitating the application of the first agent or the like to the body surface, or any member such as the above-mentioned various cosmetics.
  • Examples of such an arbitrary member include an instruction manual, a brush, a cotton swab, a cutter, scissors, the above-mentioned various cosmetics, a cleanser for removing artificial skin from the body surface, a mirror, and the like.
  • the "instruction manual” is, for example, a packaging container for accommodating the kit, a tube for injecting the first agent, etc., in addition to the general instruction manual attached in the form of a document in the kit. It is also possible to include the one in which the instruction manual is printed on the packaging container of.
  • the kit may include, for example, these agents in separate containers to prevent contact of the first and second agents, or a container having two or more compartments. It may be contained separately in each section of. In addition, these contained agents may be configured to be applied one at a time, or may be configured to be mixed together before or during use.
  • Oil-in-water emulsified composition >> The oil-in-water emulsified composition obtained by the formulation shown in Table 1 and the production method shown below was evaluated as follows, and the results are shown in Table 1.
  • A No change in color occurred as compared with the composition immediately after preparation.
  • B There was a slight change in color as a whole as compared with the composition immediately after preparation.
  • C Compared with the composition immediately after preparation, the color was changed as a whole, or the region of less than 1/4 of the bottle was changed to black.
  • D The color did not change to black as a whole, but the color changed as a whole compared to the C evaluation, or the area of 1/4 or more and less than 1/2 of the bottle changed to black. Was there.
  • E It turned black overall, or more than half of the area of the bottle turned black.
  • Example 1 ⁇ Manufacturing method of oil-in-water emulsified composition> (Example 1) Using the formulations shown in Table 1, an oil-in-water emulsified composition was produced by the following method. Here, the numbers shown below correspond to the numbers indicating the ingredients on the left side of the formulation in Table 1.
  • the oil phase part was added to the aqueous phase part 1 and mixed uniformly to prepare a preliminary emulsion.
  • a preliminary emulsion No.
  • the aqueous phase part 2 prepared by mixing the materials of 19 was added and uniformly mixed to prepare an oil-in-water emulsified composition of Example 1.
  • Examples 2 to 12 and Comparative Examples 1 to 3 The oil-in-water emulsified compositions of Examples 2 to 12 and Comparative Examples 1 to 3 were prepared in the same manner as in Example 1 except that the formulations were changed to those shown in Table 1.
  • Example 2 When Example 1 and Example 2 were compared, the composition of Example 2 was superior in storage stability. It is considered that this is because the viscosity of the composition increased with the addition of the emollient agent. That is, it is considered that other agents capable of increasing the viscosity of the composition, for example, thickeners, can exert the same effect.
  • Example 1 When Example 1 and Example 4 were compared, the composition of Example 1 was superior in storage stability. From this result, it was found that when the silicone emulsifier is blended, it is preferable to blend the silicone emulsifier in the oil phase part instead of the aqueous phase part.
  • Example 3 When Example 1 and Example 3 were compared, the composition of Example 3 was superior in storage stability. From this result, in the emulsification composition containing a platinum catalyst, it is preferable to add an emulsifier having an emulsifying ability higher than that of the polymer emulsifier (for example, a silicone-based emulsifier) in an amount of less than 1% by mass, or not to add it. It turned out.
  • an emulsifier having an emulsifying ability higher than that of the polymer emulsifier for example, a silicone-based emulsifier
  • Example 8 When Example 1 and Example 8 were compared, the composition of Example 8 was superior in storage stability. From this result, it was found that increasing the mass ratio of the first unsaturated organopolysiloxane to the total amount of platinum further improved the storage stability. Further, when an emulsifier having an emulsifying ability higher than that of a polymer emulsifier (for example, a silicone-based emulsifier) is blended in an amount of 1% by mass or more, the mass ratio of the first unsaturated organopolysiloxane to the total amount of platinum is increased. It was also found that the storage stability could be improved.
  • a polymer emulsifier for example, a silicone-based emulsifier
  • Example 13 Artificial skin forming agent and artificial skin >> 40.5 parts by mass of divinyldimethicone of 165,000 cst as the second unsaturated organopolysiloxane, 7.9 parts by mass of hydrogen dimethicone as the hydride-functionalized polysiloxane, 6.6 parts by mass of silylated silica as the filler, 6 cst as the oil content. 45.0 parts by mass of dimethicone was uniformly mixed to prepare the first agent.
  • An artificial skin forming agent was obtained using the obtained first agent and the composition of Example 3 described above as the second agent.
  • Example of prescription of oil-in-water emulsified composition >> The following are examples of formulations of the oil-in-water emulsified composition of the present disclosure, but the present invention is not limited to these examples. Each of these was prepared by a conventional method. All of these were excellent in storage stability of the platinum catalyst at high temperatures.
  • Emulsion 1 (Component) (% by mass) Ion-exchanged water 20 1,3-butylene glycol 7 Glycerin 3 Carboxyvinyl polymer (1% sol) 10 Acrylate / Alkyl Acrylate (C10-30) Cross Polymer (1% Sol) 20 Potassium hydroxide 0.1 Niacinamide 5 Dipotassium glycyrrhizinate 0.05 Sodium metabisulfite 0.01 Sodium metaphosphate 0.01 Platinum complex dispersion 1 Divinyl Dimethicone (10cst) 5 Silica 2 Mica 2 Ethanol 12 Phenoxyethanol 0.5 Ion-exchanged water residue
  • Emulsion 2 (Component) (% by mass) Ion-exchanged water 20 1,3-butylene glycol 7 Glycerin 8 (Dimethylacrylamide / Acryloyldimethyltaurine Na) Cross Polymer 0.2 Niacinamide 5 Dipotassium glycyrrhizinate 0.2 0.2 Sodium metabisulfite 0.01 Sodium metaphosphate 0.01 Platinum complex dispersion 1 Divinyl Dimethicone (10cst) 5 Ethanol 10 Phenoxyethanol 0.5 Ion-exchanged water residue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Birds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La divulgation concerne une composition d'émulsion de type huile dans l'eau contenant un catalyseur de platine, ladite composition présentant une stabilité de stockage élevée du catalyseur de platine sous des températures élevées.　La composition d'émulsion de type huile dans l'eau selon la présente divulgation comprend un milieu de dispersion contenant de l'eau et des gouttelettes d'huile dispersées dans le milieu de dispersion, les gouttelettes d'huile comprenant : un composant huileux, un émulsifiant et un catalyseur ; le composant huileux comprenant un premier polyorganosiloxane insaturé ; le catalyseur comprenant un complexe de platine coordonné avec du 1,3-divinyltétraméthyldisiloxane ; et le rapport en masse du premier polyorganosiloxane insaturé à la quantité totale de platine dans le complexe de platine étant de 200 ou plus.
PCT/JP2021/043041 2020-12-07 2021-11-24 Composition d'émulsion de type huile dans l'eau contenant un catalyseur au platine et son procédé d'utilisation Ceased WO2022124079A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022568170A JPWO2022124079A1 (fr) 2020-12-07 2021-11-24
CN202180074880.5A CN116437972A (zh) 2020-12-07 2021-11-24 包含铂催化剂的水包油型乳化组合物及其使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020202760 2020-12-07
JP2020-202760 2020-12-07

Publications (1)

Publication Number Publication Date
WO2022124079A1 true WO2022124079A1 (fr) 2022-06-16

Family

ID=81974444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/043041 Ceased WO2022124079A1 (fr) 2020-12-07 2021-11-24 Composition d'émulsion de type huile dans l'eau contenant un catalyseur au platine et son procédé d'utilisation

Country Status (3)

Country Link
JP (1) JPWO2022124079A1 (fr)
CN (1) CN116437972A (fr)
WO (1) WO2022124079A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115558298A (zh) * 2022-09-30 2023-01-03 浙江佳华精化股份有限公司 一种高效铂金催化剂母粒及其制备方法
WO2024154597A1 (fr) * 2023-01-19 2024-07-25 株式会社 資生堂 Composition huile dans l'eau pour second agent d'agent filmogène de type revêtement
WO2025105304A1 (fr) * 2023-11-17 2025-05-22 株式会社 資生堂 Agent de formation de film de type revêtement, kit comprenant ledit agent de formation, et procédé d'utilisation dudit agent de formation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3715334A (en) * 1970-11-27 1973-02-06 Gen Electric Platinum-vinylsiloxanes
JPS4889960A (fr) * 1972-02-16 1973-11-24
JP2013536861A (ja) * 2010-08-31 2013-09-26 リビング プルーフ，インコーポレーテッド 皮膚用組成物およびその使用方法
JP2017523283A (ja) * 2014-07-23 2017-08-17 ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ シリコーンエラストマー組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3576748B2 (ja) * 1997-04-30 2004-10-13 東レ・ダウコーニング・シリコーン株式会社 硬化シリコーン粉末の製造方法
JP2016180039A (ja) * 2015-03-24 2016-10-13 旭化成ワッカーシリコーン株式会社 剥離フィルムコーティング用水中油型シリコーンエマルジョン組成物及びこれを用いた剥離フィルム
CN113662885B (zh) * 2015-11-09 2024-01-30 株式会社资生堂 用于在皮肤上应用的组合物和方法
KR102187370B1 (ko) * 2018-11-26 2020-12-04 한국생산기술연구원 불균일계 나노촉매를 이용한 스킨케어용 필름의 제조방법
CN115243733B (zh) * 2020-03-17 2024-11-12 株式会社资生堂 人造皮肤形成用组合物及其使用方法
US20230218501A1 (en) * 2020-07-02 2023-07-13 Shiseido Company, Ltd. Compositions and methods for application over skin
JPWO2022215531A1 (fr) * 2021-04-07 2022-10-13
WO2022215533A1 (fr) * 2021-04-07 2022-10-13 株式会社 資生堂 Second agent d'agent de formation de film de correction de corps de type revêtement comprenant des premier et second agents, et agent de formation de couche de lubrifiant à appliquer sur le film de correction de corps

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3715334A (en) * 1970-11-27 1973-02-06 Gen Electric Platinum-vinylsiloxanes
JPS4889960A (fr) * 1972-02-16 1973-11-24
JP2013536861A (ja) * 2010-08-31 2013-09-26 リビング プルーフ，インコーポレーテッド 皮膚用組成物およびその使用方法
JP2017523283A (ja) * 2014-07-23 2017-08-17 ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ シリコーンエラストマー組成物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115558298A (zh) * 2022-09-30 2023-01-03 浙江佳华精化股份有限公司 一种高效铂金催化剂母粒及其制备方法
CN115558298B (zh) * 2022-09-30 2023-06-30 浙江佳华精化股份有限公司 一种高效铂金催化剂母粒及其制备方法
WO2024154597A1 (fr) * 2023-01-19 2024-07-25 株式会社 資生堂 Composition huile dans l'eau pour second agent d'agent filmogène de type revêtement
WO2025105304A1 (fr) * 2023-11-17 2025-05-22 株式会社 資生堂 Agent de formation de film de type revêtement, kit comprenant ledit agent de formation, et procédé d'utilisation dudit agent de formation

Also Published As

Publication number Publication date
CN116437972A (zh) 2023-07-14
JPWO2022124079A1 (fr) 2022-06-16

Similar Documents

Publication Publication Date Title
US10441527B2 (en) Fluid compositions and personal care
CN104136498B (zh) 新型液体有机聚硅氧烷及其用途
KR101005468B1 (ko) 수중유형 유화 모발 화장료
CN101808618B (zh) 含疏水硅氧烷-有机凝胶共混物的个人护理组合物
JP5383035B2 (ja) アミノ酸変性オルガノポリシロキサンエマルジョンの製造方法
JP5667332B2 (ja) 化粧料製造用組成物、化粧料および含水化粧料の製造方法
US20240156692A1 (en) Oil-in-water composition for second agent for coating-type body corrective film formation agent
WO2022124079A1 (fr) Composition d'émulsion de type huile dans l'eau contenant un catalyseur au platine et son procédé d'utilisation
JP2013010934A (ja) 新規オルガノポリシロキサンエラストマー及びその利用
JP4160165B2 (ja) ポリオルガノシロキサンエマルジョンおよびそれを用いる化粧料
CN115243733A (zh) 人造皮肤形成用组合物及其使用方法
WO2022215533A1 (fr) Second agent d'agent de formation de film de correction de corps de type revêtement comprenant des premier et second agents, et agent de formation de couche de lubrifiant à appliquer sur le film de correction de corps
WO2017188309A1 (fr) Nouvel organopolysiloxane ou sel de neutralisation d'acide de celui-ci, et utilisations de ceux-ci
US20180064630A1 (en) Pituitous silicone fluid composition
EP3448528B1 (fr) Polyorganosiloxane réticulé et composition de soins personnels contenant celui-ci
KR20230007491A (ko) O/w 에멀젼 및 이로부터 전환된 w/o 에멀젼, 및 이를 함유하는 퍼스널 케어 조성물
JP4136963B2 (ja) 毛髪化粧料
WO2023037984A1 (fr) Agent de formation de films de correction corporelle de type à application
WO2022030284A1 (fr) Agent de couche de base pour film correcteur corporel de type revêtement et son procédé d'utilisation
JP2021165263A (ja) 化粧方法
JP2025119949A (ja) 化粧料、及び該化粧料を含む塗布型皮膜形成化粧料
WO2024142934A1 (fr) Agent de formation de revêtement de type application et kit qui comprend ledit agent de formation
WO2025105223A1 (fr) Agent filmogène pour une application et kit comprenant ledit agent de formation
JP4400215B2 (ja) 新規な高分子界面活性剤を含む化粧料及び毛髪用化粧料
WO2023037983A1 (fr) Méthode pour améliorer la perméation cutanée d'un médicament hydrosoluble

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21903183

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022568170

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21903183

Country of ref document: EP

Kind code of ref document: A1